Unicycive Therapeutics is a biotechnology business based in the US. Unicycive Therapeutics shares (UNCY) are listed on the NASDAQ and all prices are listed in US Dollars. Unicycive Therapeutics employs 9 staff and has a trailing 12-month revenue of around $951,000.
How to buy Unicycive Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – UNCY. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Unicycive Therapeutics stock price (NASDAQ: UNCY)
Use our graph to track the performance of UNCY stocks over time.Unicycive Therapeutics shares at a glance
Latest market close | $0.55 |
---|---|
52-week range | $0.40 - $1.64 |
50-day moving average | $0.63 |
200-day moving average | $0.74 |
Wall St. target price | $9.38 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.95 |
Buy Unicycive Therapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Unicycive Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Unicycive Therapeutics price performance over time
Historical closes compared with the close of $0.5529 from 2023-02-07
1 week (2023-02-02) | 8.41% |
---|---|
1 month (2023-01-09) | 22.87% |
3 months (2022-11-09) | -10.82% |
6 months (2022-08-09) | -36.45% |
1 year (2022-02-09) | -61.34% |
---|---|
2 years (2021-02-05) | N/A |
3 years (2020-02-05) | N/A |
5 years (2018-02-05) | N/A |
Unicycive Therapeutics financials
Revenue TTM | $951,000 |
---|---|
Gross profit TTM | $0 |
Return on assets TTM | -64.58% |
Return on equity TTM | -131.08% |
Profit margin | 0% |
Book value | $0.31 |
Market capitalisation | $8.3 million |
TTM: trailing 12 months
Unicycive Therapeutics share dividends
We're not expecting Unicycive Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Pfizer (PFE.US) (3.75% forward annual dividend yield)
- Johnson-and-Johnson (JNJ.US) (2.69% forward annual dividend yield)
Unicycive Therapeutics overview
Unicycive Therapeutics, Inc. , a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. .
Unicycive Therapeutics in the news
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
Frequently asked questions
What percentage of Unicycive Therapeutics is owned by insiders or institutions?Currently 41.391% of Unicycive Therapeutics shares are held by insiders and 18.269% by institutions. How many people work for Unicycive Therapeutics?
Latest data suggests 9 work at Unicycive Therapeutics. When does the fiscal year end for Unicycive Therapeutics?
Unicycive Therapeutics's fiscal year ends in December. Where is Unicycive Therapeutics based?
Unicycive Therapeutics's address is: 4300 El Camino Real, Los Altos, CA, United States, 94022 What is Unicycive Therapeutics's ISIN number?
Unicycive Therapeutics's international securities identification number is: US90466Y1038
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert